Storia in 2 fonti

GSK to license Hutchmed’s dual-action cancer drug for $110M upfront

GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust clearance.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo8 g fa

GSK to license Hutchmed’s dual-action cancer drug for $110M upfront

GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust clearance.

originale

biopharmadive.com8 g fa

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

Leggi questa versione → originale

Timeline cronologica

giovedì 3 settembre 2026·biopharmadive.com
GSK wagers up to $1.3B on a different kind of cancer drug
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
giovedì 3 settembre 2026·endpoints.news
GSK to license Hutchmed’s dual-action cancer drug for $110M upfront
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust clearance.